CXCL9 as a Prognostic Inflammatory Marker in Early-Stage Lung Adenocarcinoma Patients.

ABSTRACT: Background: This study was performed to evaluate the value of inflammatory biomarkers in predicting the prognosis of early-stage (stage IA-IIB) lung adenocarcinoma. Methods: Ten inflammatory biomarkers were tested with a Luminex bead-based assay in early-stage lung adenocarcinoma patients who underwent resection. Results: A total of 152 early-stage lung adenocarcinoma patients were analyzed in this study. The mean patient age (SD) was 59.9 (9.4) years. In total, 58.6% of patients were females, and never smokers accounted for 84.0%. Lung adenocarcinoma patients with high CXCL9 levels had a 71% reduced risk of recurrence relative to patients with low CXCL9 levels (HR = 0.29, 95% CI: 0.13-0.64, p = 0.0021). After Bonferroni correction, CXCL9 remained signifi

SUBMITTER: Zhang Y 

PROVIDER: S-EPMC7347039 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature